Perrigo near-term outlook has improved, says RBC Capital RBC Capital expects Perrigo to benefit from several positive catalysts, including lower buyside expectations, tailwinds for the company's consumer health business, and increased focus on its Tysabri SPMS opportunity. The firm keeps a $160 price target and Outperform rating on the shares.
Perrigo would be good acquisition for Teva, says RBC Capital RBC Capital views Perrigo (PRGO) as an attractive acquisition target and says in a note to investors that it thinks a takeover could be a good strategic fit with solid accretion for Teva (TEVA). Teva has interest in over-the-counter products and its growth rate would be boosted by the merger, RBC believes. The firm assumes a $200 per share value for Perrigo in its acquisition assumptions. Shares of the over-the-counter and generic pharmaceuticals company closed yesterday at $153.77.